BREAST CANCER

A Prospective, Randomized, Double-Blind, Stratified, Placebo-Controlled, Multi-Center, 3-arm Trial of the Continued Efficacy and Safety of Zometa® (every 4 weeks vs. every 12 weeks vs. placebo) in Patients with Documented Bone Metastases from Breast Cancer

COLORECTAL CANCER

A Phase III Multi-Center, Randomized, Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) plus Bevacizumab versus Leucovorin and 5-FU plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma.

A multicenter, randomized double-blind placebo controlled phase III study of the efficacy of Xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV

MDS

Phase 2, Randomized, Open-Label Study To Assess the Safety and Efficacy of Weekly (QW) or Once Every Two Week (Q2W) Dosing of Epoetin Alfa (PROCRIT®) in Anemic Subjects with Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NON-HODGKIN’S LYMPHOMA

A Phase II, Multicenter, Single-Arm Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (REVLIMID®) in Subjects with Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma

NON-SMALL CELL LUNG CANCER

A Phase II, Non-randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Pre-Surgical Therapy in Treatment-Naiive Subjects with State IA or IB, Resectable Non Small Cell Lung Cancer (NSCLC)

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive non-small cell lung cancer.

REGISTRY

An observational Study of Avastin ® (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer

ANEMIA

A Randomized, Open Label, Comparative Study of Epoetin Alfa (PROCRIT ®) 80,000 Units or 120,000 Units Q3W Versus Darbepoetin Alfa (ARANESP ®) 500 mcg Q3W in Anemic Cancer Subjects Receiving Chemotherapy